The isoprostanes: A perspective

Prostaglandins

Volumn 54, Issue 6, 1997, Pages 823-851

  Rokach, J ^a   Khanapure, S P ^a   Hwang, S W ^a   Adiyaman, M ^a   Lawson, J A ^b   Fitzgerald, G A ^b  

^a FLORIDA INSTITUTE OF TECHNOLOGY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

12 iso PGF(2 ); 8 iso PGF(2 ); Eicosanoids; iP; iPF(2 ) VI; Isoprostanes; Oxidant stress; Prostaglandins

Indexed keywords

8 ISOPROSTAGLANDIN E2; 8 ISOPROSTAGLANDIN F2 ALPHA; ARACHIDONIC ACID DERIVATIVE; FREE RADICAL; ICOSAPENTAENOIC ACID; ISOLEUKOTRIENE DERIVATIVE; ISOPROSTANE DERIVATIVE; LEUKOTRIENE DERIVATIVE; NATURAL PRODUCT; POLYUNSATURATED FATTY ACID; PROSTAGLANDIN DERIVATIVE; UNCLASSIFIED DRUG;

BODY FLUID; DRUG CLASSIFICATION; DRUG STRUCTURE; DRUG SYNTHESIS; GAS CHROMATOGRAPHY; HUMAN; LIPID PEROXIDATION; MASS SPECTROMETRY; MOUSE; NOMENCLATURE; NONHUMAN; OXIDATIVE STRESS; OXYGENATION; RAT; REVIEW; THROMBOCYTE FUNCTION; VASOCONSTRICTION;

EID: 0031408488     PISSN: 00906980     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-6980(97)00183-4     Document Type: Article

References (99)

1. Samuelsson B. Structure, biosynthesis, and metabolism of prostaglandins. Wakil S.J. Lipid Metabolism. 1970;107-153 Academic Press, New York.
2. Willis A.L. CRC Handbook of Eicosanoids Prostaglandins and Related Lipids, Vol. 1, Part B . 1987;CRC Press, Boca Raton.
3. Smith W.L., Garavito R.M., DeWitt D.L. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J. Biol. Chem. 271:1996;33157-33160.
4. 2 synthase-1. Nature. 367:1994;243-249.
5. Dinchuck J.E., Car B.D., Focht R.J., Johnston J.J., Jaffee B.D., Covington M.B., Contel N.R., Eng V.M., Collins R.J., Czerniak P.M., Gorry S.A., Trzaskos J.M. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature. 378:1995;406-409.
6. Kurumbail R.G., Stevens A.M., Gierse J.K., McDonald J.J., Stegeman R.A., Pak J.Y., Gildehaus D., Miyashiro J.M., Penning T.D., Seibert K., Isakson P.C., Stallings W.C. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature. 384:1996;644-648.
7. Oshima M., Dinchuk J.E., Kargman S.L., Oshima H., Hancock B., Kwong E., Trzaskos J.M., Evans J.F., Taketo M.M. Suppression of intestinal polyposis in ape knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell. 87:1996;803-809.
8. Murata T., Ushikubi F., Matsuoka T., Hirata M., Yamasake A., Sugimot Y., Ichikawa A., Aze M.Y., Tanka T., Yoshida N., Ueono A., Oh-ishi S., Narumlya S. Altered pain perception and inflammatory response in mice lacking prostacyclin recepter. Nature. 338:1997;678-683.
9. Ford-Hutchinson A.W. New highly selective cyclooxygenase-2 inhibitors. Bazan N., Botting J., Vane J. New Targets in Inflammation. 1996;55-62 Kluwer Academic Publishers and William Harvey Press, London.
10. Murphy R.C., Hammarstrom S., Samuelsson B. Leukotriene C A slow-reacting substance from murine mastocytoma cells . Proc. Natl. Acad. Sci. USA. 76:1979;4275-4279.
11. Ford-Hutchinson A.W., Bray M.A., Shipley M.E., Doig M., Smith M.J.H. Leukotriene B, a potent chemokinetic, and aggregating substance released from polymorphonuclear leukocytes. Nature. 286:1980;264-265.
12. Willis A.L. CRC Handbook of Eicosanoids Prostaglandins and Related Lipids, Vol. 1, Part A . 1987;CRC Press, Boca Raton.
13. Rokach J., Adams J. Synthesis of leukotrienes and lipoxygenase products. Acc. Chem. Res. 18:1985;87-93.
14. Rokach J. Leukotrienes and Lipoxygenases, Chemical, Biologic and Clinical Aspects. 1989;1-518 Elsevier Science, Amsterdam, The Netherlands.
15. 4-receptor antagonist. N. Engl. J. Med. 323:1990;1736-1739.
16. 4 synthase: A homodimeric glutathione S-transferase composed of 18-kDa subunits. Proc. Natl. Acad. Sci. USA. 90:1993;2015-2019.
17. 4 synthase. Proc. Natl. Acad. Sci. USA. 91:1994;9745-9749.
18. 4. Proc. Natl. Acad. Sci. USA. 91:1994;7663-7667.
19. 4 synthase. Eur. J. Biochem. 238:1996;606-612.
20. Fitzsimmons B.J., Adams J., Evans J.F., Leblanc Y., Rokach J. The lipoxins Stereochemical identification and determination of their biosynthesis . J. Biol. Chem. 260:1985;13008-13012.
21. Adams J., Fitzsimmons B.J., Girard Y., Leblanc Y., Evans J.F., Rokach J. Enantiospecific, and stereospecific synthesis of lipoxin A. Stereochemical assignment of the natural lipoxin A and its possible biosynthesis. J. Am. Chem. Soc. 107:1985;464-469.
22. Rokach J., Fitzsimmons B. The lipoxins. Int. J. Biochem. 20:1988;753-758.
23. Serhan C.N. Lipoxins, and novel aspirin-triggered 15-epi-lipoxins (ATL). A jungle of cell-cell interactions or a therapeutic opportunity? Prostaglandins. 53:1997;107-137.
24. Wu S., Moomaw C.R., Tomer K.B., Falck J.R., Zeldin D.C. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J. Biol. Chem. 271:1996;3460-3468.
25. Makita K., Takahashi K., Karara A., Jacobson H.R., Falck J.R., Capdevila J.H. Experimental and/or genetically controlled alterations of the renal microsomal cytochrome P450 epoxygenase induce hypertension in rats fed a high salt diet. J. Clin. Invest. 94:1994;2414-2420.
26. 2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc. Natl. Acad. Sci. USA. 87:1990;9383-9387.
27. Morrow J.D., Harris T.M., Roberts L. II. Noncyclooxygenase oxidative formation of a series of novel prostaglandins: Analytical ramifications for measurement of eicosanoids. Anal. Biochem. 184:1990;1-10.
28. 2-isoprostanes) are formed in situ on phospholipids. Proc. Natl. Acad. Sci. USA. 89:1992;10721-10725.
29. Morrow J.D., Roberts L.J. II. Quantification of noncyclooxygenase derived prostanoids as a marker of oxidative stress. Free Rad. Biol. Med. 10:1991;195-200.
30. 2α. A novel strategy for the synthesis of isoprostanes. J. Am. Chem. Soc. 116:1994;10829-10830.
31. Nanji A.A., Khwaja S., Tahan S.R., Sadrzadeh S.M.H. Plasma levels of a novel noncyclooxygenase-derived prostanoid (8-isoprostane) correlate with severity of liver injury in experimental alcoholic liver disease. J. Pharmacol. Exp. Ther. 269:1994;1280-1285.
32. 2α. J. Biol. Chem. 270:1995;9800-9808.
33. 2α-I and its identification in biological fluids. Tetrahedron Lett. 37:1996;4849-4852.
34. 2α, is formed in vivo. Biochim. Biophys. Acta. 1210:1994;244-248.
35. Hecker M., Ullrich V., Fischer C., Meese C.O. Identification of novel arachidonic acid metabolites formed by prostaglandin H synthase. Eur. J. Biochem. 169:1987;113-123.
36. Patrignani P., Panara M.R., Cipollone F., Greco A., Ciabattoni G., Patrono C. Induction of prostaglandin endoperoxide synthase 2 in monocytes of human whole blood is associated with cyclooxygenase-dependent isoprostane formation. J. Invest. Med. 43:1995;335A.
37. 2α by human monocytes. J. Biol. Chem. 271:1996;8919-8924.
38. 2 in guinea pig liver. I. Identification of seven metabolites. J. Biol. Chem. 245:1970;5107-5114.
39. Taylor P.L. The 8-isoprostaglandins. Evidence for eight compounds in human semen. Prostaglandins. 17:1979;259-267.
40. 2, by lung and liver microsomes from pregnant rabbits. Biochim. Biophys. Acta. 575:1979;335-349.
41. Porter N.A., Funk M.O. Peroxy radical cyclization as a model for prostaglandin biosynthesis. J. Org. Chem. 40:1975;3614.
42. O'Connor D.E., Mihelich E.D., Coleman M.C. Stereochemical course of the autoxidative cyclization of lipid hydroperoxides to prostaglandin-like bicyclo endoperoxides. J. Am. Chem. Soc. 106:1984;3577-3584.
43. 2α via the corresponding endoperoxide by a biomimetic cyclization. Tetrahedron Lett. 25:1984;5013.
44. Tappel A.L. Lipid peroxidation damage to cell membrane. Fed. Proc. 32:1985;1870-1874.
45. 2α in humans. J. Biol. Chem. 271:1996;20617-20620.
46. 2 receptors. J. Clin. Invest. 90:1992;136-141.
47. 2α, in Rabbit Lung In Situ. H660-H663, 1992.
48. 2α, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonist. Prostaglandins. 44:1992;155-163.
49. 2 receptors in human platelets. J. Pharmacol. Exp. Ther. 270:1994;1192-1196.
50. 2α is not mediated by thromboxane receptor isoforms. J. Biol. Chem. 271:1996;14916-14924.
51. 2α increases platelet adhesion and the expression of adhesion molecules. Thromb. Haemostasis Supplement. 1:1997;844.
52. Barry P., Pratico D., Lawson J.A., FitzGerald G.A. Transcellular activation of platelets and endothelial cells by arachidonic acid in platelet microparticles. J. Clin. Invest. 99:1997;2118-2127.
53. 2 in reocclusion following coronary thrombolysis with tissue type plasminogen activator. Proc. Natl. Acad. Sci. USA. 86:1989;7585-7589.
54. 2α Specific analysis of an isoeicosanoid as an index of oxidant stress in vivo . Br. J. Clin. Pharmacol. 42:1996;15-19.
55. 2α generation during coronary reperfusion A potential quantitative marker of oxidant stress in vivo . Circulation. 95:1997;2492-2499.
56. 2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N. Engl. J. Med. 332:1995;1198-1203.
57. Reilly M., Delanty N., Lawson J.A., FitzGerald G.A. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation. 94:1996;19-25.
58. 2α, an index of oxidant stress in vivo. J. Invest. Med. 44:1996;223.
59. 2-isoprostanes) in plasma and low density lipoprotein exposed to oxidative stress in vitro. J. Clin. Invest. 93:1994;998-1004.
60. 2-isoprostanes during the oxidative modification of low density lipoprotein. Biochem. Biophys. Res. Commun. 20:1994;338-343.
61. 2-isoprostanes during aortic endothelial cell-mediated oxidation of low density lipoprotein. FEBS Lett. 348:1994;297-300.
62. 2-isoprostanes furing oxidation of human low-density lipoprotein and plasma by peroxynitrite. Circ. Res. 77:1995;335-341.
63. 2α in familial hypercholesterolemia Evidence of oxidative stress . Circulation. 94:1996;3727.
64. 2α: An index of oxidative stress in vivo. Circulation. 94:(Suppl):1996;277.
65. FitzGerald G.A., Tigges J., Barry P., Lawson J.A. Markers of platelet activation and oxidant stress in atherothrombotic disease. Thrombosis and Haemostasis. 78:1997;280-284.
66. Stephens N. Anti-oxidant therapy for ischaemic heart disease. Where do we stand? Lancet. 349:1997;1710-1711.
67. Hennekens C.H., Buring J.E., Manson J.E., Stampfer M., Rosner B., Cook N.R., Belanger C., LaMotte F., Gaziano J.M., Ridker P.M., Willett W., Peto R. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N. Engl. J. Med. 334:1996;1145-1149.
68. Hertog M.G.L., Feskens J.M., Hollman P.C.H., Katan J.B., Kromhout D. Dietary antioxidant flavanoids and risk of coronary heart disease The Zutphen elderly study . Lancet. 342:1993;1007-1011.
69. Stephens N.G., Parson A., Schofield P.M., Kelly F., Cheeseman K., Mitchinson M.J., Brown M.J. Randomized controlled trial of vitamin E in patients with coronary disease Cambridge heart antioxidant study (CHAOS) . Lancet. 347:1996;781-786.
70. Levine M., Conry-Cantilene C., Wang Y., Welch R.W., Wahsko P.W., Dhariwal K.R., Park J.B., Lazarev A., Graumlich J.F., King J., Cantilena L.R. Vitamin C pharmacokinetics in healthy volunteers. Evidence for a recommended dietary allowance. Proc. Natl. Acad. Sci. USA. 93:1996;3704-3709.
71. Princen H.M.G., Poppel G.V., Vogelezang C., Buytenhek R., Kok F.J. Supplementation of vitamin E but not β-carotene in vivo protects low density lipoprotein from lipid peroxidation in vitro. Effect of cigarette smoking. Arteriosclerosis and Thrombosis. 12:1992;554-562.
72. 2α-III. Tetrahedron Lett. 38:1997;3339-3342.
73. 2α. Tetrahedron Lett. 37:1996;779-782.
74. Porter, N.A., Lehman, L.S., Weber, B.A., Smith, K.J. Unified mechanism for polyunsaturated fatty acid autoxidation. Competition of peroxy radical hydrogen atom abstraction, β-scission, and cyclization. J. Am. Chem. Soc. 103:6447-6445; 1981.
75. Beckwith A.L.J., Lawrence T., Serelis A.K. Stereoselective ring closure of substituted Hex-5-enyl radicals. J. Chem. Soc. Chem. Commun. 484:1980.
76. Beckwith A.L.J., Schiesser C.H. Regio- and stereo-selectivity of alkenyl radical ring closure. A theoretical study. Tetrahedron. 41:1985;3925-3941.
77. Porter N.A., Zuraw P.J., Sullivan J.A., Gross P.M. Peroxymercuration-demercuration of lipid hydroperoxides. Tetrahedron Lett. 25:1984;807-810.
78. 2, a chemical analog of the biosynthetic pathway. Tetrahedron Lett. 35:1994;539-542.
79. Roberts L.J. II, Morrow J.D. The isoprostanes: Novel markers of lipid peroxidation and potential mediators of oxidant injury. Advances in Prostaglandin, Thromboxane and Leukotriene Research. 23:1995;219-224.
80. Morrow J.D., Awad J.A., Wu A., Zackert W.E., Daniel V.C., Roberts L. II. Nonenzymatic free radical-catalyzed generation of thromboxane-like compounds (isothromboxanes) in vivo. J. Biol. Chem. 271:1996;23185-23190.
81. 2, on the platelet thromboxane/endoperoxide receptor in humans and rats: Additional evidence for the existence of a unique isoprostane receptor. Prostaglandins. 1994;247-256.
82. 2α on the rabbit lung in vivo. Prostaglandins. 53:1997;69-82.
83. Harrison K.A., Murphy R.C. Isoleukotrienes are biologically active free radical products of lipid peroxidation. J. Biol. Chem. 270:1995;17273-17278.
84. Zamboni R., Milette S., Rokach J. Stereospecific synthesis of 11S,12S-oxido-5Z,7E,9E,14Z-eicosatetraenoic acid. Tetrahedron Lett. 25:1984;5835-5838.
85. 4, a biogenic precursor to the lipoxins. Tetrahedron Lett. 28:1987;3449-3452.
86. Reinke L.A., Lai E.K., DuBose C.M., McCay P.B. Reactive free radical generation in vivo in heart and liver of ethanol-fed rats Correlation with radical formation in vitro . Proc. Natl. Acad. Sci. USA. 84:1987;9223-9227.
87. Cederbaum A.I. Role of lipid peroxidation and oxidative stress in alcohol toxicity. Free Rad. Biol. Med. 7:1989;537-539.
88. Ekstrom G., Ingelman-Sundberg M. Rat liver microsomal NADPH-supported oxidase activity and lipid peroxidation dependent on ethanol-inducible cytochrome P450. Biochem. Pharmacol. 38:1989;1313-1319.
89. Bondy S.C., Guo S.X. Effect of ethanol treatment on indices of cumulative oxidative stress. Eur. J. Pharmacol. 270:1994;349-355.
90. Recknagel R.O., Glende E.A. Spectrophotometric method of lipid conjugated dienes. Methods Enzymol. 105:1984;331-337.
91. Teare J.P., Greenfield S.M., Watson D., Punchard N.A., Miller N., Rice-Evans C.A., Thompson R.P.H. Lipid peroxidation in rats chronically fed ethanol. Gut. 35:1994;1644-1647.
92. Kamimura S., Gaal K., Britton S., Bacon B.R., Triadafilopoulos G., Tsukamoto H. Increased 4-hydroxylnonenal levels in experimental alcoholic liver disease. Association of lipid peroxidation with liver fibrogenesis. Hepatology. 16:1992;448-453.
93. Odeleye O.E., Eskelson C.D., Watson R.R., Mufti S.I., Chvapil M. Vitamin E reduction of lipid peroxidation pProducts in rats fed cod liver oil, and ethanol. Alcohol. 8:1991;273-277.
94. Rondot B., Durand T., Girard J.P., Rossi J.C., Schio L., Khanapure S.P., Rokach J. A free radical route to syn lactones and other prostanoid intermediates in isoprostaglandin synthesis. Tetrahedron Lett. 34:1993;8245-8248.
95. Unpublished results.
96. Mulzer J., Kermanchahi A.K., Buschmann J., Luger P. Asymmetric synthesis of ent-corey lactone alcohol and its 12-(all-cis)- and 11-epimers via free radical 5-exo-trig-C,C cyclization. Liebigs Ann. Chem. 1994;531-539.
97. 2α by the controlled, one-step, palladium-promoted, intramolecular coupling of three different alkenes. J. Am. Chem. Soc. 113:1991;7815-7816.
98. Vionnet J.-P., Renaud P. Facile preparation of (±)-12-epi-prostaglandins from 7-oxabicyclo[2.2.1]hept-5-en-2-one via an all-cis-formyllactone related to corey lactone. Helv. Chim. Acta. 77:1994;1781-1790.
99. 2α ethyl ester. J. Org. Chem. 62:1997;194-198.